Centogene_Logo.png
CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World
04 janv. 2022 08h00 HE | Centogene NV
The CentoCloud solution is a cloud-based Software as a Service (SaaS) platform that enables laboratories around the world to analyze, interpret, and report genomic variants, and will be able to...
Centogene_Logo.png
CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery
23 déc. 2021 08h00 HE | Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
06 oct. 2021 08h00 HE | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...
CENTOGENElogo.jpg
CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects
29 sept. 2021 17h05 HE | CENTOGENE GmbH
Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 familiesEnabled testing of successful targeted therapeutic...
CENTOGENElogo.jpg
CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021
01 sept. 2021 06h30 HE | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development
27 juil. 2021 06h30 HE | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
25 juin 2021 06h30 HE | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENElogo.jpg
CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years
22 juin 2021 06h30 HE | CENTOGENE GmbH
Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeuticsFocuses on leveraging its unique rare...
CENTOGENElogo.jpg
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event
16 juin 2021 06h30 HE | CENTOGENE GmbH
Recorded revenues of €65.0 million in Q1 2021, driven by revenues from COVID-19 testing, up over 400% compared to €12.1 million in Q1 2020Achieved positive adjusted EBITDA, driven by COVID-19 testing...
CENTOGENElogo.jpg
CENTOGENE Announces Virtual Investor Event
07 juin 2021 06h30 HE | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...